Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics

24 Apr 2023

Abstract excerpt

TP53-mutant acute myeloid leukemia (AML) respond poorly to currently available treatments, including venetoclax-based drug combinations and pose a major therapeutic challenge. Analyses of RNA sequencing and reverse phase protein array datasets revealed significantly lower BAX RNA and protein levels in TP53-mutant compared to TP53-wild-type (WT) AML, a finding confirmed in isogenic CRISPR-generated TP53-knockout...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Advanced biosensing and bioanalysis techniques
Share to CRISPR and Genetic Engineering

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37088806
DOI: 10.1038/s41408-023-00830-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimeticsPMID 37088806Read ↗

The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML CellsSemantic proximity Read ↗

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemiasSemantic proximity Read ↗

<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockadeSemantic proximity Read ↗

Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugsSemantic proximity Read ↗

BH3 Mimetics in Hematologic MalignanciesSemantic proximity Read ↗

Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cellsSemantic proximity Read ↗

Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML CellsSemantic proximity Read ↗

Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.Semantic proximity Read ↗

Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid LeukemiaSemantic proximity Read ↗

Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivitySemantic proximity Read ↗

Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.Semantic proximity Read ↗

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignanciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.